Coldstream Capital Management Inc. bought a new position in shares of Natera, Inc. (NASDAQ:NTRA – Free Report) during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm bought 2,347 shares of the medical research company’s stock, valued at approximately $305,000.
A number of other institutional investors have also recently bought and sold shares of NTRA. Itau Unibanco Holding S.A. acquired a new stake in shares of Natera during the second quarter worth $28,000. Quarry LP raised its stake in shares of Natera by 148.4% in the 2nd quarter. Quarry LP now owns 318 shares of the medical research company’s stock valued at $34,000 after purchasing an additional 190 shares during the period. Covestor Ltd lifted its holdings in shares of Natera by 34.3% in the third quarter. Covestor Ltd now owns 372 shares of the medical research company’s stock valued at $47,000 after purchasing an additional 95 shares in the last quarter. GAMMA Investing LLC boosted its position in shares of Natera by 32.7% during the third quarter. GAMMA Investing LLC now owns 430 shares of the medical research company’s stock worth $55,000 after buying an additional 106 shares during the period. Finally, True Wealth Design LLC bought a new position in shares of Natera during the third quarter worth about $57,000. Institutional investors own 99.90% of the company’s stock.
Natera Trading Up 0.1 %
Shares of NASDAQ:NTRA opened at $166.55 on Monday. Natera, Inc. has a 52-week low of $57.22 and a 52-week high of $175.63. The company has a debt-to-equity ratio of 0.33, a quick ratio of 4.23 and a current ratio of 4.39. The company has a market capitalization of $21.99 billion, a P/E ratio of -94.63 and a beta of 1.63. The company has a 50-day simple moving average of $144.02 and a 200 day simple moving average of $124.66.
Insider Activity at Natera
In other Natera news, CEO Steven Leonard Chapman sold 4,523 shares of the stock in a transaction dated Tuesday, October 15th. The shares were sold at an average price of $130.40, for a total value of $589,799.20. Following the transaction, the chief executive officer now directly owns 191,163 shares of the company’s stock, valued at $24,927,655.20. This represents a 2.31 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Jonathan Sheena sold 3,000 shares of the firm’s stock in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of $125.67, for a total transaction of $377,010.00. Following the sale, the insider now owns 57,432 shares of the company’s stock, valued at $7,217,479.44. This trade represents a 4.96 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 132,963 shares of company stock worth $21,250,107. Company insiders own 7.60% of the company’s stock.
Wall Street Analyst Weigh In
Several research firms have commented on NTRA. Piper Sandler boosted their target price on Natera from $150.00 to $200.00 and gave the company an “overweight” rating in a research note on Monday, November 18th. Craig Hallum increased their target price on shares of Natera from $121.00 to $157.00 and gave the stock a “buy” rating in a report on Wednesday, November 13th. Morgan Stanley raised their target price on shares of Natera from $132.00 to $176.00 and gave the company an “overweight” rating in a research report on Thursday, November 14th. Robert W. Baird boosted their price target on shares of Natera from $120.00 to $160.00 and gave the stock an “outperform” rating in a research report on Wednesday, November 13th. Finally, Canaccord Genuity Group raised their price objective on Natera from $150.00 to $165.00 and gave the company a “buy” rating in a report on Wednesday, November 13th. One research analyst has rated the stock with a sell rating and fifteen have given a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $152.67.
View Our Latest Stock Analysis on Natera
Natera Company Profile
Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.
Read More
- Five stocks we like better than Natera
- Investing in Construction Stocks
- Dave & Buster’s: Is It Time to Make Another Play on This Stock?
- 3 Healthcare Dividend Stocks to Buy
- Why Hershey Stock Has More Room to Run Despite Takeover Rejection
- What is a support level?
- Texas Instruments: The Old-School Tech Titan Still Delivering
Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.